Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

Several fibroblast growth factor receptor (FGFR) inhibitors are approved or in clinical development for the treatment of FGFR-driven urothelial cancer, and molecular mechanisms of resistance leading to patient relapses have not been fully explored. We identified 21 patients with FGFR-driven urotheli...

Descripción completa

Detalles Bibliográficos
Autores principales: Facchinetti, Francesco, Hollebecque, Antoine, Braye, Floriane, Vasseur, Damien, Pradat, Yoann, Bahleda, Rastislav, Pobel, Cédric, Bigot, Ludovic, Déas, Olivier, Florez Arango, Juan David, Guaitoli, Giorgia, Mizuta, Hayato, Combarel, David, Tselikas, Lambros, Michiels, Stefan, Nikolaev, Sergey I., Scoazec, Jean-Yves, Ponce-Aix, Santiago, Besse, Benjamin, Olaussen, Ken A., Loriot, Yohann, Friboulet, Luc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481128/
https://www.ncbi.nlm.nih.gov/pubmed/37377403
http://dx.doi.org/10.1158/2159-8290.CD-22-1441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481128/
https://www.ncbi.nlm.nih.gov/pubmed/37377403
http://dx.doi.org/10.1158/2159-8290.CD-22-1441

Ejemplares similares